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As the second most recurring cancer in men globally, prostate cancer is a major concern to men’s 
health. It is estimated that approximately 1.3 million new cases are diagnosed every year, those cases 
are leading to the casualties of nearly 360,000 men during 2018, which represents about 3.8% of all 
male cancer related deaths. Increasing of age among men can be correlated with global prostate 
cancer incidence and mortality, with the average age of diagnosis is 66 years old. Prostate cancer is 
usually asymptomatic or with minimal symptoms in the early stages of the disease, during this period 
there is minimal to no need of treatment. At early stage, the symptoms of prostate cancer are similar 
to those observed in prostatic hypertrophy. But in more advanced stages of prostate cancer, more 
painful symptoms may appear. Elevated levels of Prostate Specific Antigen (PSA) are the main 
marker used to detect prostate cancer. The disease can be confirmed with a biopsy of the prostate 
gland. In this work, we try to review the prostate cancer’s causes, epidemiology, aetiology, and risk 
factors globally, as we think that it is a pivotal way to keep update our understanding on this 
increasingly important health threat to men.  
 




Prostate cancer is considered to be the second most recurring cancer in men globally, with estimated 
1,276,106 new cases and a leading to 358,989 casualties (3.8% of all casualties by cancer in men) 
during 2018 [1,2]. Global Prostate Cancer incidence and mortality is correlated with increasing age, 
66 years is the average age when diagnosed. To be noted, the incidence rate is higher in African-
American men when compared to white men, with almost 159 new cases diagnosed per 100,000 men 
and with a mortality rate of almost double than White men [3]. This variation is hypothetically 
attributed to the differences in social, environmental and genetic aspects. While 2,293,818 new cases 
are expected until 2040, there will be a small variation in mortality with an increase of 1.05% [4]. 
Globally prostate cancer is the second most familiar and fifth-most hostile neoplasm among male 
individuals. One of the emerging issues in men is prostate cancer. The Prostate is a ductal small 
walnut-shaped gland situated in men below the urinary bladder that produces the seminal fluid for 
sperms provision and transportation. The risk of emerging prostate cancer during the man’s lifetime is 
one out of seven. According to the epidemiological studies, different environmental and genetic 
factors are associated with the progression of abnormal prostate cell growth which ultimately causes 
the development of cancerous cells [210,211]. Many risk factors have been implicated in the etiology 
of cancer including; tobacco and alcohol consumption, unhealthy diet, physical inactivity, viral 
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A prostate cancer patient may not present any symptoms at the early stages of the disease and 
usually has an indolent course, and probably needs minimal or no treatment at all. Still, the most 
frequent complaint presented is difficulty of urination, increased frequency, and nocturia, all these 
symptoms may show in prostatic hypertrophy. Later in advanced stages of the disease more 
symptoms may arise, like urinary retention and back pain.  
 
Prostate cancer is mainly detected on the basis of increased plasma levels of prostate-specific 
antigen (PSA > 4 ng/mL), which is a glycoprotein expressed normally by the prostate tissue. Due to 
the fact the men without prostate cancer may express elevated levels of PSA, a tissue biopsy is better 
used to confirm the cancer’s case. Numerous countries have implemented a PSA-based screening to 
better understand the differences in incidence and mortality rates and trends. In the USA, it was 
recommended by the American Cancer Society [5] and the American Urological Association in 2009 
[6] that males at an average risk, aged ≥ 50 years, with life expectancy of ≥ 10 years to give a 
decision about undertaking PSA testing after being informed about the benefits, uncertainties and 
associated risks of testing. In 2013, the European Association of Urology and the Prostate Cancer 
Foundation of South Africa both gave a recommendation that PSA screening should be offered to 
men with life expectancy of 10 years at least [7,8].  
 
Physical activity and dietary intake are major influencers in the development and progression of 
prostate cancer. Global ethnic variation in the incidence rates of prostate cancer may be attributed to 
dietary factors [9-13].  
 
As a great deal of studies are trying to identify the genes and mutations behind prostate cancer, it will 
be very beneficial to have a detailed analysis of prostate cancer epidemiology and risk factors 
evaluation in order to understand the connection between genetic mutations and the role of the 
environment in triggering such mutations towards tumor progression. Having more comprehension 
and understanding of etiology and causative risk factors of prostate cancer will give us more means to 
identify males who are at risk and may lead to better development of more effective screening and 








Prostate cancer incidence rate differs across various regions and populations (fig. 1) [2]. In 2018, the 
number of new prostate cancer registered reached 1,276,106 cases, depicting 7.1% of all cancers in 
males [1]. Prostate cancer incidence rates vary highly globally. The age-standardized rate exhibited 
the highest levels in Oceania (79.1 per 100,000 people) and North America (73.7), they were followed 
be Europe (62.1). Africa and Asia contrarily have lower incidence rates than those from developed 
countries (26.6 and 11.5, respectively) [2]. A difference of 190-fold was seen between the populations 
with the highest incident rates (France, Guadeloupe, 189.1) and the ones with the lowest rate 
(Bhutan, 1.0) [2].  
 
As age increases, the incidence of prostate cancer increases [2]. Even though only 1 in 350 males 
aged under 50 will be diagnosed with prostate cancer [14], the incidence rate will go up to 1 male in 
every 52 males aged between 50 to 59. The incidence rate is almost 60% in men aged 60 and over 
[15].  
 
The causes of these variations amongst countries is not entirely understandable. The global variations 
in the incidence of prostate cancer might be accounted to PSA tested [16]. As an example, in Europe, 
24% of all new cancers diagnosed in men were prostate cancer cases in 2018, with estimated 
450,000 new prostate cancer cases to be diagnosed in 2018 [17]. On the other hand in the USA, 
prostate cancer is considered to be the second most common cancer responsible for 9.5% of all new 
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research studies have shown that that about 20-40% of prostate cancer cases registered in the USA 
and Europe could be attributed to overdiagnosis made through the vast PSA testing [16,19,20].  
 
As shown in many studies, the highest incidence of prostate cancer globally is in African-American 
males, they are more prone to develop prostate cancer earlier in life when compared to other racial 
and ethnic groups [21]. Caribbean and Black males in Europe also reflect the same data as African-
Americans, this suggest that they share a common genetic background more susceptible to the 
development of cancer. To be noted, Chu et al [22] revealed that African-American males have 40 
times the incidence rate than those in Africa. These variations propose that environmental factors also 
may contribute an important role in the etiology of prostate cancer and differences in incidence may 




Fig. 1. International variation in age-standardized prostate cancer incidence rates  




Prostate cancer international mortality rates markedly differ worldwide (Fig. 2) [2]. In 2018, mortality 
rates highest level was documented in Central America (10.7 per 100,000 people), then came 
Australia and New Zealand (10.2) and Western Europe (10.1) [2]. On the other hand, the lowest rates 
were recorded in the Asian countries (South-Central, 3,3, Eastern, 4.7, and South-Eastern, 5.4) and 
Northern Africa (5.8) [2]. One-third of prostate cancer deaths were in Asia (33.0%, 118,427 of deaths), 
Europe followed by (29.9%, 107,315 of deaths). Prostate cancer mortality rate increases with age, 
and almost 55% of all deaths happen after 65 years of age [2]. 
 
US Preventive Task Force (USPSTF, 2018) has announced that PSA screening can potentially be 
effective in decreasing deaths attributed to prostate cancer in males aged 55 – 69 years [23]. 
Unfortunately, the data are less convincing for men over 70 years of age of all races [24]. The highest 
prostate cancer incidence and mortality rates are in African-American males. This proposes that not 
only African-American males may have some specific genes that are more prone to mutations in 
prostate cancer, but generally these mutations are linked to a more aggressive type of cancer. Oliver 
in 2007 [25] noted that African-American males were less likely to identify early symptoms of prostate 




Prostate cancer incidence and mortality temporal trends differed in a significant matter during the past 
years, and they look tightly correlated to the endorsement of PSA testing for early disease detection 
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Fig. 2. International variation in age-standardized prostate cancer mortality rates 
Source: GLOBOCAN 2018 [2] 
 
Incidence rates in the USA, Australia, and Canada have shown an increase between the 1980s and 
1990s but now is showing a decline due to fast distribution of PSA testing [25,26]. On the other hand, 
European countries exhibit a slight increase in incidence rates due to the increased understanding of 
PSA screening and starting to gradually adopt PSA testing, without undermining the probability of 
other factors being involved, like diet and ultraviolet radiation overexposure [27]. 
  
Interestingly, prostate cancer incidence will tend towards an increase globally with 1,017,712 new 
cases (+79.9% overall change) up to 2040 is estimated (Table I) [4]. Africa will have the highest 
incidence of prostate cancer with (+120.6%), to be followed by Latin America and the Caribbean 
(+101.1%) and Asia (100.9%). On the other hand, Europe will have the lowest incidence rate at 
{+30%). This increase in the incidence rate may be attributed to an increased life expectancy. 
Developing countries increased incidence rates may be due to better access to medical services as 
well as increased reporting and documentation of cases. Finally, increasing incidence rates in these 
regions where PSA is not performed on a routine base suggests that this event exhibit westernization 
of the lifestyle including physical inactivity, obesity and dietary factors [28].  
 
Table 1. Estimated Number of incident cases from 2018 to 2040, prostate Cancer, Males, all 
ages 
 
 2018 2040  












Latin America and the 
Caribbean Males (APC 
0%)  






North America Males 
(APC 0%)  




Europe Males (APC 
0%)  












Data obtained from GLABOCAN 2018 [4]. 
 
Prostate cancer mortality rates in most western countries including North America and in Western and 
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possibly reflects both early detection and treatment improvement [29-31]. O the other hand, in the 
USA, a randomized controlled trial recently failed to show benefits of PSA testing in lowering down 
prostate cancer deaths, although another research study conducted in Europe demonstrated benefits 
of PSA testing [32,33]. Analysis of ethnicity-specific showed that the decline in mortality in African-
American males was higher than that in White males during 2001 and 2015 [15,34]. A study by 
Negoita et al suggested that newer and improved modalities of cancer detection and treatments and 
improved treatment of resistant and metastatic prostate cancer may explain this trend [24].  
 
It is estimated that during the period from 2018 to 2040 the mortality rate will double with 379,005 
deaths globally [4]. Africa will have the highest mortality rate with (+124.4%), to be followed by Asia 
(116.7%), while Europe will have the lowest estimated mortality rate with (+58.3%) [4]. The finding 
above is not unusual, due to the lack of resources for screening and detection of prostate cancer 
which makes it fairly likely of being detected during the late stages. Additionally, lack of accessibility to 
medical care in developing countries, may give a possible reasoning for the high mortality despite the 
lower incidence.  
 
2.4 Survival  
 
Despite prostate cancer incidence rates are elevated, much prostate cancer cases are identified when 
the cancer is still confined inside the prostate. In the USA, the 5-year survival rate for males 
diagnosed with cancer is near 98% [15]. On the other hand, data collected from the Eurocare project 
(EUROCARE-5) of patients diagnosed with prostate cancer through the interval from 2003 to 2007 
demonstrated that the 5-year survival rates were 83% [17]. Eastern European countries had a survival 
rate of 76%, where it rises to 88% in Southern and Central European countries. Additionally, survival 
has risen over time in all over Europe with the largest improvement being noticed in Eastern 
European countries [35]. 
 
2.5 Etiology and Risk Factors 
 
Unlike common cancers, the etiology of prostate cancer is largely unknown despite many studies 
aimed towards it. Yet, it was established that advanced age, ethnicity, genetic factors and family 
history are risk factors of prostate cancer [36-38]. Amongst positively linked risk-factors are diet 
(saturated animal fat and red meat consumption, decreased consumption of vegetables, fruits, 
vitamins and coffee), obesity and decreased physical activity, hyperglycemia, inflammation, infections 
and being subjected to chemicals or ionizing radiation in the environment [37, 39-43].  
 
2.6 Age  
 
Prostate cancer is considered to be the most commonly diagnosed cancer amongst elderly males [1]. 
More elderly men are diagnosed with prostate cancer due to the fact that life expectancy and PSA 
screening has increased. The risk increases particularly in white males aged 50 and above who have 
no familial history of prostate cancer, and in black males aged 50 and above who also have no familial 
history [18]. It was noticed that 30% of males aged 50 and above who have deceased to reasons 




Different racial groups highly vary in prostate cancer prevalence. In the USA for example, American 
Indian/Alaskan demonstrate the lowest incidence (46.9), whilst in Native and Asian/Pacific Islanders 
(52.4), to be followed by White (93.3). Finally, African-American men have the highest incidence rate 
at (157.6) [15]. 
 
This variance can be explained by both socioeconomic states and biologic factors [45]. As an 
example, African-American males have less access to good health services which leads to 
inadequate PSA screening [46]. To be noted, when compared to White males, considerably higher 
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As proposed by numerous studies, genetic predisposition may be a factor. For instance, African-
American males have a certain chromosome (8q24 variants), which correlates with elevated prostate 
cancer risk [49-52]. Also, high rate of genetic variation in African-American males leads to tumor 
suppression such as EphB2 [53] or that control cell apoptosis such as BCL2 [54]. In addition, a more 
aggressive form of the cancer is shown in African-American males, which also can be attributed to 
genetic and biologic differences, putting in mind the lack of proper screening and delayed 
presentation [45].  
 
2.8 Family History and Genetic Factors  
 
Family history is demonstrated in 20% of prostate cancer patients, it may develop not only due to 
shared genes but also for similar type of exposure to environmental carcinogens and similar lifestyle 
manners [55,56]. Some studies have shown that increased risk for prostate cancer is correlated with 
inherited genetic background, responsible for 5% of disease risk [57,58].  
 
Studies of gene linkage demonstrate high susceptibility loci for prostate carcinoma on genes in seven 
distinct loci. Chromosome 1q24-25 that is known as HPC1 gene encodes the enzyme ribonuclease L 
(RNASEL) [59], which plays a role in the intrinsic immune defense mechanisms and the interferon 
(IFN)-mediated signaling [60]. It has a major role in the reduction of antiviral activity and the regulation 
of cell apoptosis [61]. To be noted, analyzing samples of human prostate cancer with RNASEL 
mutations revealed the presence of retrovirus, which indicates the importance of antiviral defenses to 
the development of prostate cancer [62]. In addition, discovering of retroviral infection in a number of 
prostate cancer cases also demonstrated the possible connection of chronic retroviral infection and 
the resultant inflammation of the tissue with cancer initiation [63,64]. HPC2/ELAC2 gene which is 
another HPC gene was found on chromosome 17p11 and encodes a protein with insufficiently 
understood function [65]. ELAC2, a gene participating in the development of prostate cancer by 
binding SMAD2, which leads to the up-regulation of the proliferation through TGF-beta signaling 
pathway activation [66]. Macrophage scavenger receptor 1 (MSR1) is the third identified HPC gene, it 
is located on chromosome 8p22 [67]. Although, due to the low penetrance of this allele , a number of 
studies were unsuccessful to prove it association with HPC [68,69]. In addition, an HPC subset was 
noted to occur in males with BRCA1 and 2 mutations that demonstrated a form of prostate cancer that 
was clinically aggressive [70]. Furthermore, BRCA2 mutations were linked with an increased prostate 
cancer incidence, and PALB2, BRCA2-interacting protein, were engaged in familial prostate cancer 
[71].  
 
Another player in prostate cancer inheritance is the X chromosome, due to the fact that it contains the 
androgen receptor (AR) and due to small deletions in Xq26.3-q27.3 region were detected in hereditary 
and sporadic types of prostate cancer [72,73]. The latest studies on 301 families affected with 
hereditary prostate cancer showed a number of other loci that may have a role to hereditary prostate 




Dietary factors may have a key role in prostate cancer development as shown by many studies on 
immigrants relocating for developing countries (low-risk areas) to industrialized countries (higher risk), 
that demonstrated that changing to a western lifestyle started a shift towards prostate cancer 
incidence increase. For example, it was reported that incidence rate in African-Americans is higher by 
40 times when compared to those of Africa [22]. On the other hand, Chinese males living in the USA 
have an incidence rate for prostate cancer 16 times higher than males in China [75], implementing 
that environmental factors may possess a vital role.  
 
Numerous studies show that certain foods are associated at increased risk, while others play a 
protective role. 
 
Saturated animal fat: Numerous ecological studies have demonstrated a positive correlation 
between the mortality of prostate cancer and intake of meat per individual, fat and dairy products [76, 
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consumption of total fat was correlated with a statistically significant increase in the risk of prostate 
cancer [78].  
 
There are a number of biological mechanisms that are thought to be implicated between saturated 
animal fat consumption and prostate cancer risk: 1) encouraging prostate carcinogenesis through 
androgen; 2) elevating the levels of reactive oxygen species (ROS) and rising the levels of 
leukotrienes and prostaglandins from lipid metabolism; 3) enhancing basal metabolism, insulin growth 
factor and tumor proliferation.  
 
High-calorie consumption of saturated animal fat has led to elevate the growth of prostate cancer cells 
by rising the circulating levels of androgen [79,80]. Additionally, randomized cross-over studies about 
low-fat and high-fat diets demonstrated that the androgen level is lower post-prandial and in 
vegetarians [81]. Finally, a number of studies mentioned that reducing lipid level in the diet reduces 
testosterone levels [82-84].  
 
Extra fat leads to an increase in oxidative stress and ROS levels that will attack the cells leading to 
peroxidation and finally DNA damage. Lipid metabolism and its metabolite have an observed role in 
mice, it has been found that dietary fat is an essential modulator of the growth of prostate cancer. For 
instance, while a number of studies did not show any differences in tumor growth and survival of mice 
feeding on a Western diet, other studies mentioned a delay in the growth of cancer cells in mice 
feeding on low-fat corn-oil diets, implying that both amount and type of fat are critical [85].  
 
Corn-oil may endorse cancer growth through linoleic acid, which has the most omega-6 fat in the oil. 
Arachidonic acid, a metabolite of linoleic acid, initiates the formation of many pro-inflammatory 
prostaglandins (PG), amongst is PGE2 which promotes proliferation of the cells, and 5-
hydroxyeicosatetraenoic acid which is a result of 5-lipoxygenase action, which is known to be highly 
expressed in malignant prostate cancer. Therefore, decreasing omega-6 fatty acid consumption can 
decreased cancer growth. Oemga-3 fats are known to have advantageous effects against cancer 
growth in opposite to omega-6 pro-inflammatory effect [86]. 
 
Red meat: Prostate cancer has been associated with dietary meat consumption when comparing 
cancer incidence and mortality with meat consumption per capita [87]. It has been shown that a 
weekly consumption of five or more servings of processed meat lead to a higher risk of prostate 
cancer when compared to a one or less serving weekly, This has not been the case in African-
Americans [88]. On the other hand, consuming meat at a high temperature lead to a 20% increase in 
the risk of non-advanced prostate cancer [89]. Chemical compounds such as aromatic hydrocarbons 
and mutagenic heterocyclic amines can be formed due to high temperature cooking [90,91]. Lipid 
peroxidating and DNA damaging compounds such as N-nitroso compounds can formed by grilling or 
barbecuing meat [92,93].  
 
Milk, dairy products and calcium: From a genetic aspect, dairy foods have been correlated with 
high prostate cancer risk [88,94-97]. Calcium from dairy and from supplements both contribute to a 
higher risk of prostate cancer in men. A dose of more than 2,000 mg daily of calcium was linked to an 
elevated risk of prostate cancer [98].  
 
Vegetables: It was established that there is great correlation between Brassica vegetables and 
prostate cancer reduction. It is believed that they have prostate cancer reducing characteristics. 
These anticancer characteristics are due to presence of phenylethyl isothiocyanate, sulphoraphane, 
phytochemicals and indole-3-carbinol [99]. On the other hand, some studies showed no anticancer 
characteristics of Brassica vegetables [100-103].  
 
Green tea and soy: Compared to North America, Asia has a low prostate cancer incidence rate. 
Knowing that green tea and soy a big part of their diet, studies were initiated to discover their 
promising cancer prevention potential. Consuming green tea and soy has been noted in decreased 
levels of prostate cancer amongst other cancers [104-107]. Catechins observed in green tea and 
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carcinogenesis [108,109] and metastasis [110-112]. In addition, polyphenols found in green tea leads 
to a reduction of IGF-1 levels [113-115].  
 
Tomatoes: Prostate cancer risk seems to be reduced by tomatoes. Due to their high content of 
lycopene which possesses high anticancer characteristics in addition to cancer-preventive traits [116-
120]. In addition, lycopene exerts its action on the androgen receptor receptors and overturns 
dihydrotestosterone’s effects and also leads to the inhibition of insulin growth factor (IGF-I)-stimulation 
via Akt and GSK3β and GSK3 tyrosine phosphorylation [121].  
 
Decreased risk of prostate cancer is associated with both tomato consumption and lycopene intake 
[122]. Oppositely, no clinical benefit has been found of lycopene in an open phase II study of 
advanced prostate cancer [123]. Two other small epidemiological studies have shown the same 
results [124,125]. Therefore, additional studies need to be conducted to explore the connection 
between tomatoes consumption and prostate cancer risk. 
 
2.10 Vitamin and Mineral Supplements 
 
Vitamin D: The relationship between sun light (UVB exposure) and prostate cancer incidence has 
been found as inversed [126,127], implying that prostate cancer risk development might be increased 
by vitamin D deficiency [128]. Likewise, studies have showed that people residing in countries with 
sunny climates are at lower risk of acquiring secondary solid cancer after melanoma in comparison to 
people residing in countries with less sun exposure [129].  
 
Vitamin D has a role in the growth of the prostate, as supported by biochemical evidence [130,131]. 
Vitamin D and its analogues can inhibit cell proliferation and invasion, and promote cellular 
differentiation and apoptosis in prostate cancer cells, also in tumor progression in animal models [131-
133]. Such discoveries suggests the use of vitamin D and its analogues as alternative therapeutic 
agents for prostate cancer if the androgen deprivation therapy is unsuccessful [134].  
 
Selenium: Selenium is considered to be an essential micronutrient. It can be found in plants such as 
tubers, cereals and legumes, it can also be found in animal products such as meat, eggs and seafood 
in the form of selenomethionine and selenocysteine. Many cancers, including prostate cancer, are 
inversely associated with selenium.  
 
A number of studies indicate that high consumption of selenium can lead to a 50-60% reduction of 
prostate cancer risk when compared with low selenium consumption [135,136]. The NPC trial has 
demonstrated that men consuming selenium have 50% reduction in prostate cancer incidence [137]. 
Selenomethionine exerts its action on cancer cells inducing cell cycle arrest [138,139]. Inducing 
apoptosis and inhibiting angiogenesis is another way it can act [139,140]. Methylseleninic acid 
induces apoptosis through a caspase-mediated pathway [141].  
 
Folate and vitamin B12: Decreased levels of folate and vitaminB12 can cause modified methylation 
and cause cancer growth due to reason that these essential vitamins play a role in DNA methylation, 
synthesis and repair [142]. The role of folate in developing an aggressive type of prostate cancer is 
represented in in vitro [143], in vivo [144] and genetic studies [145,146]. In addition, increased serum 
concentration of folate was correlated with an elevated proliferation of prostate cancer cells, this was 
founded in some samples gathered from patients who had radical prostatectomy surgery [147]. 
  
Nevertheless, it was reported in a recent meta-analysis that elevated concentrations of vitamin B12 
and folate give a low 12% increase in prostate cancer risk [148]. In prostate cancer patients, folate 
consumption does not have any effect on disease progression [149], or survival [150]. To conclude, 
further investigation is needed to determine the association between vitamin B12 and folate and 
prostate cancer.  
 
3. ALCOHOL CONSUMPTION 
 
It has been noticed that there is a relationship between alcohol consumption and many types of 
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tend to be a risk factor for many malignancies including prostate cancer [152]. On the other hand, 
many cohort studies imply that there is a weak relationship between alcohol consumption and 
prostate cancer mortality [153-156], whereas no relationship with increased risk was found by other 
studies [157]. Contradictory to that, a considerable correlation between elevated alcohol consumption 
and prostate cancer risk was found, with a relative risk (RR) valued from 1.05 to 1.21 for one or four 
drinks containing alcohol daily, respectively [158,159].  
 
Coffee: Increased prostate cancer risk has been inversely correlated with coffee consumption. It was 
shown in observational studies and a number of animal studies that there is a correlation between 
long-term coffee consumption and better glucose metabolism and secretion of insulin [160].  
 
It was showed by a large prospective study that coffee consumption was inadequately inversely 
correlated with overall prostate cancer risk, whereas it considerably decreased the risk of lethal and 
advanced prostate cancer when comparing people who extensively consume coffee to those who 
consume less coffee [161].  
 
Obesity, physical activity and insulin: Prostate of the aggressive and advanced types was found to 
be linked to obesity [162,163]. Also, high body mass index (BMI) is found to be correlated with a more 
aggressive type of prostate cancer and a worse outcome [122,164]. 
 
This can probably be justified by the change of circulating concentrations of metabolic and sex steroid 
hormones in obese males, which are recognized to play a role in the development of the prostate as 
well as oncogenesis [165].  
 
The development of insulin resistance with decreased glucose uptake can be caused by obesity, 
especially when it is combined with physical inactivity. As a result, it will cause chronically increased 
levels of inulin in the blood. Insulin is known as a hormone the stimulates growth and proliferation, 
therefore it can be considered as a risk factor that may promote the initiation and/or progression of 
prostate cancer [166]. Furthermore, adipose cells are considered to be a source of inflammation an 
addition to macrophages present in adipose, which in turn secrete inflammatory mediators [167]. It 
was shown by three meta-analysis studies that there is a small but steady correlation between obesity 
and prostate cancer incidence regardless of BMI increase [168]. Three national surveys conducted in 
the USA represented data that implied that obesity is correlated with a more aggressive type of 
prostate cancer and an elevated mortality in spite of the lower incidence [169].  
 
Diagnosing obese men with prostate cancer could be challenging, as their circulating plasma levels 
are higher which leads to haemodilution of PSA [170]. Eventually, undergoing a biopsy is less likely 
which will lead to a later detection until a late advanced stage [166,168].  
 
Physical activity is thought to be the simplest adjustable risk factor to handle, as it possesses many 
advantages and less side effects that lead to the prevention of prostate cancer. A study shows a 
significant lower risk of prostate cancer in ex-soldiers who exercised [171].  
 
Cigarette smoking: Exposure to cigarette smoking, both passive and active, is deemed to be 
carcinogenic for many types of human cancers [172].  
 
Linking smoking to prostate cancer may be attributed to either a hormonal or some unknown genetic 
factors. For example, elevated levels of sex hormones in male smokers may elevate the risk of 
prostate cancer or assist in cancer progression [173,174]. Alternatively, functional polymorphisms 
found in genes engaged in polycyclic aromatic hydrocarbons (PAHs) metabolism, one of the 
chemicals found in cigarette smoke that is carcinogenic [172], may exert an effect on cancer onset 
and progression [175].  
 
Epidemiological studies have failed to establish a relationship between smoking and prostate cancer 
incidence. On the other hand, an number of cohort studies have noted a 2-3 fold increase in risk in 
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Insulin and insulin-like growth factor: Malignancies such as breast, pancreatic and colorectal 
cancers have been positively correlated to hyperglycaemia [178]. Though, its relationship with 
prostate carcinogenesis is inconsistent. Numerous studies discovered proof of elevated risk of more 
aggressive prostate cancer amongst males with unusual levels of glucose, with the correlation found 
not significant in two of the studies [179-182]. 
  
On the other hand, a protective effect of hyperglycaemia against advanced prostate cancer had been 
reported in several other studies [183-185]. It has been documented early on that glucose is a vital 
source of energy for fast proliferation of tumour cells [186]. Data from genetic and clinical studies 
pointed to the link between the hyperglycaemic environment and carcinogenic processes like 
apoptosis, oxidative stress, DNA damage and chronic inflammation, all may control the cancer’s 
aggressiveness and progression [187-190].  
 
Insulin directly controls serum glucose; therefore, an elevated level of glucose stimulates insulin 
secretion from the pancreas. A previous study has noted that patients with high-risk prostate cancer 
had elevated levels of insulin [191]. Lastly, the elevated level of circulating insulin leads to a lower 
level of production of insulin-like growth factor (IGF-1)- binding proteins, rises IGF-1 levels and rises 
advanced glycation production end products leading to a promoting of carcinogenesis [192].  
 
Chronic inflammation and prostatitis: It has been found that there is a strong affiliation between 
prostate cancer and inflammation, both epidemiological and biological studies supplied evidence that 
inflammation is responsible of high-grade or aggressive prostate malignancies and eventually 
metastatic spread [193,194]. The information proven by evidence-based practices thus far backs the 
function of inflammatory response in the management of tumour microenvironment via the 
remodelling of the extracellular matrix (ECM) and launching of epithelial-mesenchymal transition 
(EMT). Truly, growth factors and cytokines are released by inflammatory cells inside the tumour 
microenvironment in order to stimulate ECM’s angiogenesis and remodelling, while in the reactive 
stroma, further cytokines are released which stimulate EMT-mediated responses [195].  
 
Biopsies have shown that patients with high PSA levels frequently show intraprostatic inflammation 
[196]. Chronic prostatitis leads to proliferative inflammatory atrophy (PIA) [193], which may cause 
prostatic interepithelial neoplasia (PIN) a known prostate cancer precursor [197].  
 
Inflammation of the prostate cancer is referred to as prostatitis, it is asymptomatic, thus hard to 
diagnose [198]. It has been noted that patients diagnosed with prostate cancer usually exhibit 
prostatitis symptoms, this may be attributed to the increased frequency of biopsy [199]. A meta-
analysis of studies conducted between 1990 and 2012 provided statistical evidence that prostatitis is 
major risk factor in prostate cancer [200].  
 
Sexually transmitted disease (STD): Evidence provided by a number of epidemiological studies 
show that elements correlated to sexual conduct and STD’s may be linked with prostate cancer [201]. 
Prostatitis and prostate atrophy caused by gonorrhoea and other bacterial infections may lead to 
prostate cancer, viral infections on the other hand role may be attributed to the transforming 
properties of the viruses, especially HSV [200]. 
  
A big case-control study based on the population of the USA including African-American and white 





For high risk prostate cancer, utilising a shortened course of docetaxel as a hormonal therapy 
following radical prostatectomy (or radiation therapy) has been proven to be a safe and feasible 
choice [203][204]. The utilization of docetaxel as a hormonal therapy has been demonstrated to be 
well tolerated and with minimal toxicity [204]. Patients with an elevated risk for prostate cancer have a 
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However, long-term androgen ablation therapy targeted at prostate cancer has been associated with 
substantial adverse effects affecting both quality of life and total health [204][205].  
 
4,5-dicaffeolquinic acid, as demonstrated in studies, exerts an inhibitory effect against prostate cancer 
cells, it causes cessation of the cell cycle [205]. On the other hand, clinical trials imply that using 
docetaxel is associated with improved survival, additionally , combining docetaxel with estramustine 
give a better outcome [206]. More important, a significant number of patients undergoing docetaxel-
estramusine therapy had as much as 50% PSA decline when compared with those undergoing 
mitoxantrone- prednisone treatment [206]. Many preliminary studies suggest that carboplatin and 
oxaliplatin may have some action and could be used as a second-line route in chemotherapy [207].  
 
An oral platinum complex called satraplatin exerts its action against hormone refractory prostate 
cancer in cisplatin-resistant human tumour lines [208]. Satraplatin-prednisone therapy had a median 
overall survival of 14.9 months, compared to 11.9 months on prednisone alone, demonstrating a 
markedly decrease in PSA levels [208].  
 
It has been reported that abiraterone, enzalutamide and many other agents may paly a role in 
improving the outcomes in men treated for metastatic prostate cancer resistant to conventional 
hormonal therapy [209]. Options for treating prostate cancer are presented in Table 2.  
 
Table 2. Options treating prostate cancer 
 
Surgical Therapeutic Radiotherapy  
Radical prostatectomy Hormonal therapy Vinblastine Iridium implant 
Doxorubicin Mitomycin 
Oxaliplatin Docetaxel 





5. CONCLUSION  
 
Prostate cancer is the second most common malignancy in men, coming after lung cancer [1]. Having 
a biomarker like PSA which is correlated in positive manner to prostate cancer made a very positive 
impact on epidemiological studies of the disease. As a result of utilizing PSA as biomarker, the 
number of diagnosed cases of prostate cancer has doubled in the USA since early 80’s [209]. 
Similarly, other countries, especially western, have shown the same increase.  
 
It is possible to say that the most exciting statistic about the incidence and mortality of prostate cancer 
is the manner that prevalence fluctuates amongst various racial groups, showing the highest 
prevalence in African-American males [18]. This variation can be attributed to biologic and 
socioeconomic factors, and here comes the urge to study which genes may be involved and how do 
they correlate with the environment.  
 
In human prostate cancer recently, a thorough analysis of genetic and epigenetic alterations was 
made possible by the development of innovative genetic technologies. In combination to targeted 
functional studies, this information aided to detect key signalling pathways that are usually correlated 
to the initiation and progression of prostate cancer. These findings will give a chance for the 
development of innovative targeted methods for therapeutic interventions. More studies are carried 
out to discover genes correlated to an increased risk of prostate cancer, more insights about the role 
of specific genetic changes on prostate cancer advancement are gathered by researchers. 
  
On another aspect, not enough studies have proven that there is a correlation between dietary intake 
and risk and prevention of prostate cancer, but some preclinical studies researching the ties between 
specific eating behaviours and prostate cancer suggest that there might be a link. Hence, there is a 
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in prostate cancer. Finally, early intervention and personalised molecularly targeted approaches 
should be added to future chemoprevention studies, in order to select a treatment for patients with 
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